Health & Fitness
Health and Fitness
Health and Fitness
Tue, January 6, 2009 CytRx Announces Management Promotion
LOS ANGELES--([ BUSINESS WIRE ])--CytRx Corporation (NASDAQ: CYTR) today announced the appointment of John C. Caloz to the position of Chief Financial Officer. Former Chief Financial Officer Mitchell Fogelman resigned December 31, 2008, for personal reasons.
"I am pleased to acknowledge the contribution of John with this well-deserved promotion," said CytRx's President and CEO, Steven A. Kriegsman. "John brings extensive experience with publicly held healthcare companies and has proven his abilities while working as CytRx's Chief Accounting Officer. The considerable talent and experience of Mr. Caloz, along with his solid knowledge of CytRx, will provide strong support for the Company's further development. I would like to thank Mitchell for his contribution to CytRx through his proven leadership and managerial skills; we wish him the best in his future endeavors."
Mr. Caloz joined CytRx in October 2007 and has served as the Company's Chief Accounting Officer. Prior to joining CytRx, he served as Chief Financial Officer of publicly traded Occulogix, Inc. from 2005 to 2006 and Chief Financial Officer of publicly traded IRIS International Inc., a California medical device manufacturer, from 2001 to 2004. Prior to that, he was the Chief Financial Officer of Synarc, Inc., a medical imagining company. In 1993, he was appointed Senior Vice President, Finance, and Chief Financial Officer of Montreal-based Phoenix International Life Sciences, Inc., where he served until the company's acquisition by MDS Inc. in 1999. From 1983 to 1993, Mr. Caloz was a partner at Rooney, Greig, Whitrod, Filion & Assoc. of Saint Laurent, Quebec, a firm of Chartered Accountants specializing in R&D and high-tech companies. He earned his accounting degree from York University, Toronto, Canada and is a Chartered Accountant.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the treatment of acute promyelocytic leukemia (APL). CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. The Company owns and operates a research and development facility in San Diego. CytRx also maintains a 45% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ: RXII). For more information on the Company, visit [ www.cytrx.com ].
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties described in CytRx's Form 10-Q for the quarter ended September 30, 2008 and other recently filed SEC documents, such as its most recent annual report on Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
